Skip to content

IPP-PSP Block vs. SPSIPB in Breast Surgery

Interpectoral-pectoserratus Plane Block vs. Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesia in Patients Undergoing Breast Cancer Surgery

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07246720
Enrollment
70
Registered
2025-11-24
Start date
2025-11-15
Completion date
2026-06-30
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Postoperative Acute Pain, Regional Anesthesia

Keywords

Interpectoral-Pectoserratus Plane Block, Serratus Posterior Superior Intercostal Plane Block, Breast Cancer Surgery, Opioid Consumption, Pain Management

Brief summary

This prospective, randomized clinical study aims to compare the analgesic efficacy of the interpectoral-pectoserratus plane block and the serratus posterior superior intercostal plane block for postoperative pain management in patients undergoing breast cancer surgery. Both techniques are ultrasound-guided regional anesthesia methods targeting different interfascial planes of the thoracic wall. The study will evaluate postoperative pain scores, opioid consumption, Quality of recovery and potential complications. The findings are expected to contribute to optimizing regional anesthesia strategies for enhanced recovery and improved analgesia following breast cancer surgery.

Interventions

PROCEDUREInterpectoral-Pectoserratus Plane Block

Ultrasound-guided injection between pectoralis major-minor and pectoralis minor-serratus anterior planes.

PROCEDURESerratus Posterior Superior Intercostal Plane Block

Ultrasound-guided injection between the serratus posterior superior muscle and the intercostal muscles.

Sponsors

Zonguldak Bulent Ecevit University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18-65 years of age * ASA I-II-III risk groups * Patients with informed consent * Patients undergoing breast cancer surgery

Exclusion criteria

• Ages \<18 and \>65 * ASA ≥ IV * History of allergy to local anesthetics * Known coagulation disorders * Infection near the insertion site * Chronic analgesic use * Patients with diabetes mellitus and those receiving neoadjuvant chemotherapy (due to potential impairment of pain sensation) * Body mass index \>30 * Dementia or confusion * Lack of cooperation

Design outcomes

Primary

MeasureTime frameDescription
Cumulative opioid consumptionin the first 24 hours after completion of the surgical procedureCumulative opioid consumption in the first 24 postoperative hours after the completion of the surgical procedure

Secondary

MeasureTime frameDescription
Postsurgical Quality of Recovery measured by the Quality of Recovery questionnairefirst day after surgeryPostsurgical recovery by Quality of Recovery questionnaire (QoR-15) on first (D1) day after surgery. The minimum score on the Quality of Recovery questionnaire is 0 and the maximum score 150. Higher scores mean better quality of recovery.
Number of episodes of postoperative painIn the first 24 hours after completion of the surgical procedureNumber of episodes of postoperative pain (NRS score ≥ 4) at rest and at deep inspiration in the first 24 postoperative hours after the completion of the surgical procedure

Countries

Turkey (Türkiye)

Contacts

Primary Contactçağdaş baytar, MD
cagdasbaytar31@gmail.com+905542255960

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026